



Novel Molecular Interceptive and Therapeutic Targets and Noninvasive Prognostic and Predictive Biomarkers in Prostate Cancer

Guest Editor:

Prof. Dr. Anait S. Levenson

Department of Biomedical Sciences, College of Veterinary Medicine, Long Island University, Brookville, NY 11548, USA

Deadline for manuscript submissions:

30 April 2025

Message from the Guest Editor

This Special Issue aims to provide a comprehensive overview of the current advancements in the field of prostate cancer research, with a particular focus on novel molecular targets for detecting cancer at its very early stage or achieving partial or complete remission in advanced cancer. We invite the submission of original research articles and reviews that address prostate cancer genomic and epigenomic heterogeneity and alterations during its stage-defined progression.

The following various aspects of prostate cancer, including but not limited to, are of interest:

1. Modeling different stages of prostate cancer in genetically engineered mouse models;
2. Identification and characterization of novel molecular targets in prostate cancer;
3. Development and evaluation of targeted therapies for prostate cancer (pre-clinical and clinical studies);
4. Noninvasive prognostic and predictive biomarkers for risk assessment and treatment response evaluation, including promising urinary non-coding RNAs (miRNAs);
5. Innovative approaches for personalized medicine and precision oncology in prostate cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)